Global Ceftazidime Injection Market Research Report 2024

Publication ID:

PB505247431

Publication Date:

June 4, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Ceftazidime injection is a western medicine preparation, mainly used for respiratory tract infections and urinary tract infections caused by sensitive bacteria.Since the global outbreak of COVID-19, these drugs have also entered a stage of shortage .
The global Ceftazidime Injection market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Ceftazidime Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Ceftazidime Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Ceftazidime Injection include Teligent, Pfizer, B Braun, Sagent, WG Critical Care, GSK, Allergan, CSPC Zhongnuo Pharmaceutical and Anhui Welman, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Ceftazidime Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ceftazidime Injection.
Report Scope
The Ceftazidime Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ceftazidime Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ceftazidime Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Teligent
Pfizer
B Braun
Sagent
WG Critical Care
GSK
Allergan
CSPC Zhongnuo Pharmaceutical
Anhui Welman
Guangzhou Baiyunshan Tianxin Pharmaceutical
Hainan Hailing Chemipharma
Segment by Type
1g/vial
2g/vial
6g/vial
Segment by Application
Hospital
Clinics
Recovery Center
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ceftazidime Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ceftazidime Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Ceftazidime Injection Market Overview
1.1 Product Overview and Scope of Ceftazidime Injection
1.2 Ceftazidime Injection Segment by Type
1.2.1 Global Ceftazidime Injection Market Value Comparison by Type (2024-2030)
1.2.2 1g/vial
1.2.3 2g/vial
1.2.4 6g/vial
1.3 Ceftazidime Injection Segment by Application
1.3.1 Global Ceftazidime Injection Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Recovery Center
1.4 Global Ceftazidime Injection Market Size Estimates and Forecasts
1.4.1 Global Ceftazidime Injection Revenue 2019-2030
1.4.2 Global Ceftazidime Injection Sales 2019-2030
1.4.3 Global Ceftazidime Injection Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Ceftazidime Injection Market Competition by Manufacturers
2.1 Global Ceftazidime Injection Sales Market Share by Manufacturers (2019-2024)
2.2 Global Ceftazidime Injection Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Ceftazidime Injection Average Price by Manufacturers (2019-2024)
2.4 Global Ceftazidime Injection Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Ceftazidime Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ceftazidime Injection, Product Type & Application
2.7 Ceftazidime Injection Market Competitive Situation and Trends
2.7.1 Ceftazidime Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Ceftazidime Injection Players Market Share by Revenue
2.7.3 Global Ceftazidime Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Ceftazidime Injection Retrospective Market Scenario by Region
3.1 Global Ceftazidime Injection Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Ceftazidime Injection Global Ceftazidime Injection Sales by Region: 2019-2030
3.2.1 Global Ceftazidime Injection Sales by Region: 2019-2024
3.2.2 Global Ceftazidime Injection Sales by Region: 2025-2030
3.3 Global Ceftazidime Injection Global Ceftazidime Injection Revenue by Region: 2019-2030
3.3.1 Global Ceftazidime Injection Revenue by Region: 2019-2024
3.3.2 Global Ceftazidime Injection Revenue by Region: 2025-2030
3.4 North America Ceftazidime Injection Market Facts & Figures by Country
3.4.1 North America Ceftazidime Injection Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Ceftazidime Injection Sales by Country (2019-2030)
3.4.3 North America Ceftazidime Injection Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Ceftazidime Injection Market Facts & Figures by Country
3.5.1 Europe Ceftazidime Injection Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Ceftazidime Injection Sales by Country (2019-2030)
3.5.3 Europe Ceftazidime Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ceftazidime Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Ceftazidime Injection Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Ceftazidime Injection Sales by Country (2019-2030)
3.6.3 Asia Pacific Ceftazidime Injection Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Ceftazidime Injection Market Facts & Figures by Country
3.7.1 Latin America Ceftazidime Injection Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Ceftazidime Injection Sales by Country (2019-2030)
3.7.3 Latin America Ceftazidime Injection Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ceftazidime Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Ceftazidime Injection Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Ceftazidime Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa Ceftazidime Injection Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Ceftazidime Injection Sales by Type (2019-2030)
4.1.1 Global Ceftazidime Injection Sales by Type (2019-2024)
4.1.2 Global Ceftazidime Injection Sales by Type (2025-2030)
4.1.3 Global Ceftazidime Injection Sales Market Share by Type (2019-2030)
4.2 Global Ceftazidime Injection Revenue by Type (2019-2030)
4.2.1 Global Ceftazidime Injection Revenue by Type (2019-2024)
4.2.2 Global Ceftazidime Injection Revenue by Type (2025-2030)
4.2.3 Global Ceftazidime Injection Revenue Market Share by Type (2019-2030)
4.3 Global Ceftazidime Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global Ceftazidime Injection Sales by Application (2019-2030)
5.1.1 Global Ceftazidime Injection Sales by Application (2019-2024)
5.1.2 Global Ceftazidime Injection Sales by Application (2025-2030)
5.1.3 Global Ceftazidime Injection Sales Market Share by Application (2019-2030)
5.2 Global Ceftazidime Injection Revenue by Application (2019-2030)
5.2.1 Global Ceftazidime Injection Revenue by Application (2019-2024)
5.2.2 Global Ceftazidime Injection Revenue by Application (2025-2030)
5.2.3 Global Ceftazidime Injection Revenue Market Share by Application (2019-2030)
5.3 Global Ceftazidime Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Teligent
6.1.1 Teligent Corporation Information
6.1.2 Teligent Description and Business Overview
6.1.3 Teligent Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Teligent Ceftazidime Injection Product Portfolio
6.1.5 Teligent Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Ceftazidime Injection Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 B Braun
6.3.1 B Braun Corporation Information
6.3.2 B Braun Description and Business Overview
6.3.3 B Braun Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 B Braun Ceftazidime Injection Product Portfolio
6.3.5 B Braun Recent Developments/Updates
6.4 Sagent
6.4.1 Sagent Corporation Information
6.4.2 Sagent Description and Business Overview
6.4.3 Sagent Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sagent Ceftazidime Injection Product Portfolio
6.4.5 Sagent Recent Developments/Updates
6.5 WG Critical Care
6.5.1 WG Critical Care Corporation Information
6.5.2 WG Critical Care Description and Business Overview
6.5.3 WG Critical Care Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 WG Critical Care Ceftazidime Injection Product Portfolio
6.5.5 WG Critical Care Recent Developments/Updates
6.6 GSK
6.6.1 GSK Corporation Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GSK Ceftazidime Injection Product Portfolio
6.6.5 GSK Recent Developments/Updates
6.7 Allergan
6.6.1 Allergan Corporation Information
6.6.2 Allergan Description and Business Overview
6.6.3 Allergan Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Allergan Ceftazidime Injection Product Portfolio
6.7.5 Allergan Recent Developments/Updates
6.8 CSPC Zhongnuo Pharmaceutical
6.8.1 CSPC Zhongnuo Pharmaceutical Corporation Information
6.8.2 CSPC Zhongnuo Pharmaceutical Description and Business Overview
6.8.3 CSPC Zhongnuo Pharmaceutical Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.8.4 CSPC Zhongnuo Pharmaceutical Ceftazidime Injection Product Portfolio
6.8.5 CSPC Zhongnuo Pharmaceutical Recent Developments/Updates
6.9 Anhui Welman
6.9.1 Anhui Welman Corporation Information
6.9.2 Anhui Welman Description and Business Overview
6.9.3 Anhui Welman Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Anhui Welman Ceftazidime Injection Product Portfolio
6.9.5 Anhui Welman Recent Developments/Updates
6.10 Guangzhou Baiyunshan Tianxin Pharmaceutical
6.10.1 Guangzhou Baiyunshan Tianxin Pharmaceutical Corporation Information
6.10.2 Guangzhou Baiyunshan Tianxin Pharmaceutical Description and Business Overview
6.10.3 Guangzhou Baiyunshan Tianxin Pharmaceutical Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Guangzhou Baiyunshan Tianxin Pharmaceutical Ceftazidime Injection Product Portfolio
6.10.5 Guangzhou Baiyunshan Tianxin Pharmaceutical Recent Developments/Updates
6.11 Hainan Hailing Chemipharma
6.11.1 Hainan Hailing Chemipharma Corporation Information
6.11.2 Hainan Hailing Chemipharma Ceftazidime Injection Description and Business Overview
6.11.3 Hainan Hailing Chemipharma Ceftazidime Injection Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Hainan Hailing Chemipharma Ceftazidime Injection Product Portfolio
6.11.5 Hainan Hailing Chemipharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ceftazidime Injection Industry Chain Analysis
7.2 Ceftazidime Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ceftazidime Injection Production Mode & Process
7.4 Ceftazidime Injection Sales and Marketing
7.4.1 Ceftazidime Injection Sales Channels
7.4.2 Ceftazidime Injection Distributors
7.5 Ceftazidime Injection Customers
8 Ceftazidime Injection Market Dynamics
8.1 Ceftazidime Injection Industry Trends
8.2 Ceftazidime Injection Market Drivers
8.3 Ceftazidime Injection Market Challenges
8.4 Ceftazidime Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Teligent
Pfizer
B Braun
Sagent
WG Critical Care
GSK
Allergan
CSPC Zhongnuo Pharmaceutical
Anhui Welman
Guangzhou Baiyunshan Tianxin Pharmaceutical
Hainan Hailing Chemipharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂